Curriculum Vitae for Floyd E. Taub, M.D.
section 1
2007-Present: CEO of CytoCore, Inc. CytoCore develops cost-effective cancer screening, therapeutic and delivery systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models.
2005-Present: Founder & Director of CureImmune Corporation. CureImmune is committed to health enhancement using scientifically proven immune modulating therapies It initiated sales of a product line based on a novel an OTC drug. This product was out licensed to a larger company for up front payments royalty payments and a commitment to a major marketing campaign. Dr. Taub is assisting in further development and marketing of this product as their Biomedical Research Director He is also serving on the Scientific Advisor Board of CytoCore, Inc.
1999-Present: Founder of LifeTime™ Pharmaceuticals Inc. LifeTime™ is a clinical stage NanoDrug pharmaceutical company. LifeTime’s strategy is to in-license new drug candidates, which have already been proven effective and safe in animal tests. LifeTime™ focuses on small molecules designed to treat life-threatening diseases. It targets diseases that are "fast tracked" through the regulatory process.
Main accomplishments:
- Conducted clinical Phase I/II clinical trials of Beta LT™ (beta-alethine)
- Data presented by McGill at the American Society of Hematology indicate low toxicity and immune stimulation and anti-cancer efficacy of Beta LT.
- Early termination of Phase I/II clinical trials at McGill University/JGH due to positive results. These studies supported the mechanism of action of the drug, demonstrated biological activity in people, at low doses, defined a patient population especially suitable for treatment, and most importantly, and provided evidence of anti-cancer activity with no detectable toxicity.
- Ongoing CRADA (Cooperative Research and Development Agreement) with Battelle labs and international collaborators for the further testing and development of pharmaceutical compounds based on the active ingredients in garlic.
1997-Present: Founder FindCure.Org ( previously Victory Over Cancer and Chronic Conditions). FindCure is a non-profit organization committed to stimulate clinical development of non-toxic agents that can modulate the immune system to better fight cancer, in people and in pets. The Foundation’s motto is “Developing and Distributing New Therapies”. The focus includes lymphoma, myeloma, brain and colon cancer and other diseases in which immune systems stimulation may help. It provides free therapy to those in need.
1994-2005: Founder and Chairman of Dovetail Technologies Inc. DTI is, leading a paradigm shift by identifying and applying drugs 1 thousand to 1 million-fold more potent than conventional drugs. This Nanodrug™ technology offers ultra high potency, ultra low toxicity and virtually side effect free therapy. It reduces frequency of administration for easier and more effective patient compliance and lower cost. Dovetail engaged in research, development and commercialization of cutting edge, patented, immuno-therapeutic technologies for illnesses including cancer, hepatitis, HIV, allergies, fatigue, flu and the common cold.
Main Accomplishments
- Brought Lead Drug product to market without major outside capitalization
- Developed the technology used by LifeTime Pharmaceuticals, Inc
Dovetail’s first products, each containing Taurox™ and other ingredients were labeled for the treatment of fatigue and allergies, cold and flu. It reduced fatigue by optimizing the immune system. These products reached the market six months ahead of plan due to achieving statistically significant effects in patients with cancer, hepatitis and chronic fatigue syndrome very rapidly. Over 90% of patients experience a reduction in fatigue in clinical trials. Symptoms are typically reduced 50-66%. The product is now sold nationwide through a variety of marketing arrangements. Post marketing analysis confirms the commercial preparation has the same activities as seen in the clinical trials. The overwhelming majority of patients respond and it allows some debilitated patients to return to normal activities.
1984 -1990: Founder, CEO, President and V.P. of Research and Development, Digene Diagnostics, Inc. Guided corporate development and technical R&D during the organizations growth from 1 to 50 employees. Digene developed reagents for and clinical methods for using diagnostic DNA techniques.
Main accomplishment: Identified the need for and then conceived, designed, developed, and marketed diagnostic tests to help prevent either under treatment or unnecessary surgical treatment that results from the frequently inaccurate "PAP" smear. Digene’s tests distinguish those abnormalities which contain types of papilloma virus (HPV) of the type that cause cancer from identical appearing abnormalities which are not pre-cancerous since they do not contain oncogenic papilloma viruses. Digene still (May 2006) is the only provider of a FDA approved diagnostic for HPV typing. It has been approved as part of routine screening and has become the standard of optimal care.
Additional accomplishments at Digene:
- Raised over seven (7) million dollars.
- Negotiated a corporate partnership with Mitsubishi Petrochemical Company, Ltd., to fund R&D and to distribute Digene’s products in Japan. This arrangement retained all Digene's technology and product manufacture rights and specified "flowback" for Mitsubishi technology and products in the DNA field.
- Conceived, wrote, and executed research grants and contracts in excess of $1.3 million under the federal Small Business Innovative Research (SBIR) program. Achieved 100% success rate on Phase II applications and in completion of major project goals.
- Marketed a line of molecular biology reagents, services, and DNA probe tests. Sixteen DNA probe kits were developed.
- Designed and outfitted 3 facilities, including a 9,500 sq. ft. R+D facility built to specifications and a 10,000 sq. ft. manufacturing facility.
- Authored six patent applications and numerous disclosures in DNA probes, molecular biology and diagnostic medicine.
- Qualified DDI as the first biotechnology company to be admitted to the University of Maryland Technology Advancement Program and subsequently qualified Digene to be a "jump start" (rapid sales growth) company, as evaluated by Washington High Technology.
|